Vesnarinone (BioDeep_00000624712)

   


代谢物信息卡片


6-{4-[(3,4-dimethoxyphenyl)carbonyl]piperazin-1-yl}-1,2,3,4-tetrahydroquinolin-2-one

化学式: C22H25N3O4 (395.184497)
中文名称: 维司力农
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC
InChI: InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)

描述信息

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic
D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
D020011 - Protective Agents > D002316 - Cardiotonic Agents
D000970 - Antineoplastic Agents
D002317 - Cardiovascular Agents
D007155 - Immunologic Factors

同义名列表

2 个代谢物同义名

Vesnarinone; 6-{4-[(3,4-dimethoxyphenyl)carbonyl]piperazin-1-yl}-1,2,3,4-tetrahydroquinolin-2-one



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mariusz K Szymanski, Rudolf A de Boer, Gerjan J Navis, Wiek H van Gilst, Hans L Hillege. Animal models of cardiorenal syndrome: a review. Heart failure reviews. 2012 May; 17(3):411-20. doi: 10.1007/s10741-011-9279-6. [PMID: 21909828]
  • Benjamin W Van Tassell, Ross A Arena, Stefano Toldo, Eleonora Mezzaroma, Tania Azam, Ignacio M Seropian, Keyur Shah, Justin Canada, Norbert F Voelkel, Charles A Dinarello, Antonio Abbate. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PloS one. 2012; 7(3):e33438. doi: 10.1371/journal.pone.0033438. [PMID: 22438931]
  • Atakan Yeşil, Ebubekir Senateş, Ibrahim Vedat Bayoğlu, Emrullah Düzgün Erdem, Refik Demirtunç, Ayşe Oya Kurdaş Övünç. Red cell distribution width: a novel marker of activity in inflammatory bowel disease. Gut and liver. 2011 Dec; 5(4):460-7. doi: 10.5009/gnl.2011.5.4.460. [PMID: 22195244]
  • Neil A Smart, Alf I Larsen, John P Le Maitre, Almir S Ferraz. Effect of exercise training on interleukin-6, tumour necrosis factor alpha and functional capacity in heart failure. Cardiology research and practice. 2011 Feb; 2011(?):532620. doi: 10.4061/2011/532620. [PMID: 21403878]
  • Ignacio J Sánchez-Lázaro, Luis Almenar-Bonet, Edelmiro Reganon-Salvador, Virtudes Vila-Liante, Vicenta Martínez-Sales, Luis Martínez-Dolz, Jaime Agüero-Ramón-Llin, Antonio Salvador-Sanz. Are there differences in acute phase inflammation markers regarding the type of heart failure?. Heart international. 2011; 6(2):e17. doi: 10.4081/hi.2011.e17. [PMID: 22049314]
  • Wilfried Dinh, Reiner Füth, Werner Nickl, Thomas Krahn, Peter Ellinghaus, Thomas Scheffold, Lars Bansemir, Alexander Bufe, Michael Coll Barroso, Mark Lankisch. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovascular diabetology. 2009 Nov; 8(?):58. doi: 10.1186/1475-2840-8-58. [PMID: 19909503]
  • Stephan von Haehling, Joerg C Schefold, Ewa Jankowska, Wolfram Doehner, Jochen Springer, Kristin Strohschein, Sabine Genth-Zotz, Hans-Dieter Volk, Philip Poole-Wilson, Stefan D Anker. Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. PloS one. 2009 Jul; 4(7):e6411. doi: 10.1371/journal.pone.0006411. [PMID: 19641622]
  • Katja B Vallbracht-Israng, Ilkay Kazak, Peter L Schwimmbeck. Association of cytokines with endothelium dependent flow mediated vasodilation (FMD) of systemic arteries in patients with non-ischemic cardiomyopathy. Cardiovascular ultrasound. 2007 Dec; 5(?):49. doi: 10.1186/1476-7120-5-49. [PMID: 18070342]
  • Kumara S Sekar, Steven L Bramer. Extended application of an LC-MS/MS method for the analysis of vesnarinone and its metabolites in human urine and dialysate fluid. Journal of pharmaceutical and biomedical analysis. 2003 Nov; 33(4):711-7. doi: 10.1016/s0731-7085(03)00360-1. [PMID: 14623597]
  • Tadakazu Kondo, Yoshiko Suzuki, Toshiyuki Kitano, Kazuya Iwai, Mitsumasa Watanabe, Hisanori Umehara, Naoharu Daido, Naochika Domae, Masaro Tashima, Takashi Uchiyama, Toshiro Okazaki. Vesnarinone causes oxidative damage by inhibiting catalase function through ceramide action in myeloid cell apoptosis. Molecular pharmacology. 2002 Mar; 61(3):620-7. doi: 10.1124/mol.61.3.620. [PMID: 11854443]
  • A Deswal, N J Petersen, A M Feldman, B G White, D L Mann. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. Chest. 2001 Aug; 120(2):453-9. doi: 10.1378/chest.120.2.453. [PMID: 11502643]
  • A Patnaik, E K Rowinsky, B K Tammara, M Hidalgo, R L Drengler, A M Garner, L L Siu, L A Hammond, S A Felton, S Mallikaarjun, D D Von Hoff, S G Eckhardt. Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Dec; 18(23):3974-85. doi: 10.1200/jco.2000.18.23.3974. [PMID: 11099327]
  • S E Reis, R Holubkov, J B Young, B G White, J N Cohn, A M Feldman. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. Journal of the American College of Cardiology. 2000 Aug; 36(2):529-33. doi: 10.1016/s0735-1097(00)00738-5. [PMID: 10933368]
  • Y Katayama, A Fujita, T Ohe, I Findlay, Y Kurachi. Inhibitory effects of vesnarinone on cloned cardiac delayed rectifier K(+) channels expressed in a mammalian cell line. The Journal of pharmacology and experimental therapeutics. 2000 Jul; 294(1):339-46. doi: NULL. [PMID: 10871331]
  • S K Manna, B B Aggarwal. Vesnarinone suppresses TNF-induced activation of NF-kappa B, c-Jun kinase, and apoptosis. Journal of immunology (Baltimore, Md. : 1950). 2000 Jun; 164(11):5815-25. doi: 10.4049/jimmunol.164.11.5815. [PMID: 10820260]
  • N Ueki, T Taguchi, M Takahashi, M Adachi, T Ohkawa, Y Amuro, T Hada, K Higashino. Inhibition of hyaluronan synthesis by vesnarinone in cultured human myofibroblasts. Biochimica et biophysica acta. 2000 Feb; 1495(2):160-7. doi: 10.1016/s0167-4889(99)00161-5. [PMID: 10656973]
  • R F Frye, B Tammara, T D Cowart, S L Bramer. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. Journal of clinical pharmacology. 1999 Nov; 39(11):1177-83. doi: . [PMID: 10579149]
  • S Ishiyama, M Hiroe, T Nishikawa, T Shimojo, T Hosokawa, I Ikeda, T Toyozaki, T Kasajima, F Marumo. Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in rats. Cardiovascular research. 1999 Aug; 43(2):389-97. doi: 10.1016/s0008-6363(99)00105-4. [PMID: 10536669]
  • K Takeuchi, P J del Nido, A E Ibrahim, H Cao-Danh, I Friehs, P Glynn, D Poutias, D B Cowan, F X McGowan. Vesnarinone and amrinone reduce the systemic inflammatory response syndrome. The Journal of thoracic and cardiovascular surgery. 1999 Feb; 117(2):375-82. doi: 10.1016/s0022-5223(99)70436-8. [PMID: 9918980]
  • P N Tata, K S Schorno, T D Cowart, S L Bramer. LC/MS/MS analysis of vesnarinone and its principal metabolites in plasma and urine. Journal of pharmaceutical and biomedical analysis. 1999 Jan; 18(6):1037-45. doi: 10.1016/s0731-7085(98)00194-0. [PMID: 9925340]
  • A Suzumura, M Sawada. Effects of vesnarinone on cytokine production and activation of murine microglia. Life sciences. 1999; 64(14):1197-203. doi: 10.1016/s0024-3205(99)00051-x. [PMID: 10210262]
  • C Wandel, C C Lang, D C Cowart, A F Girard, S Bramer, D A Flockhart, A J Wood. Effect of CYP3A inhibition on vesnarinone metabolism in humans. Clinical pharmacology and therapeutics. 1998 May; 63(5):506-11. doi: 10.1016/s0009-9236(98)90101-1. [PMID: 9630823]
  • B Koneru, D T Cowart, M Noorisa, J Kisicki, S L Bramer. Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone. Journal of clinical pharmacology. 1998 May; 38(5):429-32. doi: 10.1002/j.1552-4604.1998.tb04448.x. [PMID: 9602955]
  • M Sato, H Kawamata, K Harada, K Nakashiro, Y Ikeda, H Gohda, H Yoshida, T Nishida, K Ono, M Kinoshita, M Adachi. Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene. Cancer letters. 1997 Jan; 112(2):181-9. doi: 10.1016/s0304-3835(96)04581-8. [PMID: 9066726]
  • D D Lazarus, T Kambayashi, M Yato-Kioka, H Baumann, C O Jacob, G Strassmann. Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury. International journal of immunopharmacology. 1997 Jan; 19(1):49-58. doi: 10.1016/s0192-0561(96)00052-5. [PMID: 9226479]
  • T Hirozane, A Matsumori, Y Furukawa, S Matsui, Y Matoba, S Sasayama. Prolongation of murine cardiac allograft survival with vesnarinone. Journal of molecular and cellular cardiology. 1997 Jan; 29(1):67-76. doi: 10.1006/jmcc.1996.0252. [PMID: 9040022]
  • S Sato, S Tomoyasu, J Okabe-Kado, M Hozumi, N Tsuruoka, S Nakai, M Adachi, Y Honma. Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent. Experimental hematology. 1996 Jan; 24(1):37-42. doi: NULL. [PMID: 8536790]
  • A Matsumori, S Sasayama. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments. European heart journal. 1995 Dec; 16 Suppl O(?):140-3. doi: 10.1093/eurheartj/16.suppl_o.140. [PMID: 8682082]
  • M Sato, K Harada, T Bando, T Shirakami, K Nakashiro, H Yoshida, S Nakai, K Kawai, M Adachi. Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice. Cancer letters. 1995 May; 91(1):1-9. doi: 10.1016/0304-3835(95)03713-7. [PMID: 7750082]
  • S Matsui, A Matsumori, S Sasayama. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life sciences. 1994; 55(22):1735-41. doi: 10.1016/0024-3205(94)00342-4. [PMID: 7968253]
  • H Masuoka, M Ito, M Sugioka, H Kozeki, T Konishi, T Tanaka, T Nakano. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent. Biochemical and biophysical research communications. 1993 Jan; 190(2):412-7. doi: 10.1006/bbrc.1993.1063. [PMID: 8381275]
  • S Wu, C Wu. [Solid phase clean-up and determination of vesnarinone in plasma by high performance liquid chromatography]. Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao. 1992 Mar; 23(1):106-9. doi: . [PMID: 1398618]
  • W Lueprasitsakul, S L Fang, S Alex, L E Braverman. Effect of the cardiac inotropic drug, OPC 8212, on pituitary-thyroid function in the rat. Endocrinology. 1991 Jun; 128(6):2709-14. doi: 10.1210/endo-128-6-2709. [PMID: 1903694]
  • G Miyamoto, H Sasabe, N Tominaga, N Uegaki, M Tominaga, T Shimizu. Metabolism of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212) in the rat, mouse, dog, monkey and human. Xenobiotica; the fate of foreign compounds in biological systems. 1988 Oct; 18(10):1143-55. doi: 10.3109/00498258809042237. [PMID: 3242310]
  • A Ohnishi, T Ishizaki. Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic, inotropic agent. Journal of clinical pharmacology. 1988 Aug; 28(8):719-26. doi: 10.1002/j.1552-4604.1988.tb03206.x. [PMID: 3216039]
  • S Sasayama, M Inoue, H Asanoi, K Kodama, M Hori, T Sakurai, C Kawai. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure. Heart and vessels. 1986; 2(1):23-8. doi: 10.1007/bf02060240. [PMID: 3722083]
  • G Miyamoto, H Sasabe, M Odomi, T Shimizu. High-performance liquid chromatographic procedure for the determination of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-(dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone, in human plasma and urine. Journal of chromatography. 1985 Mar; 338(2):450-5. doi: 10.1016/0378-4347(85)80120-1. [PMID: 3998030]
  • G Miyamoto, H Sasabe. Pharmacokinetics of a new positive inotropic agent, 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), in the rat, rabbit, beagle dog and rhesus monkey. Arzneimittel-Forschung. 1984; 34(3A):394-402. doi: NULL. [PMID: 6540095]